Abstract

Background/purpose Pediatric sarcomas have a poor prognosis, recur frequently, and are not effectively treated by currently available therapy. Immunotherapy is a promising treatment modality; however, to be successful, immune tolerance must be overcome. CD4 +CD25 + T cells are immunosuppressive. The authors hypothesize that immune tolerance may be overcome by eliminating the regulatory CD4 +CD25 + T cells, which are induced by tumor. Methods A murine fibrosarcoma (MF), which expresses an MHC-II-restricted tumor antigen (mL26), was injected subcutaneously. CD4 + T cells were isolated and CD25 + population examined. Monoclonal antibody was used to deplete CD25 + T cells. Proliferation to mL26 was used to determine CD4 + T cell response to tumor-associated antigen (TAA). Results Depletion of CD25 + cells prevented tumor establishment. Tumor-infiltrating CD25 + T cells, which madeup 48% of CD4 + T cells in tumors, suppressed proliferation in allogeneic mixed lymphocyte reactions. Draining lymph node cells from tumor-bearing (TB) mice did not proliferate in response to mL26, whereas those from naive mice responded vigorously. Depletion of CD25 + cells before immunization restored response to mL26 in TB mice. Conclusions CD4 +CD25 + T cells induced by MF facilitate tumor establishment and maintain immune tolerance. Depletion of CD4 +CD25 + T cells may be an effective means for reversing tumor tolerance and enhancing cancer vaccines.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.